Glasdegib Active in Heavily Pretreated Myelofibrosis

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.

In this video, Aaron Gerds, MD, of the Cleveland Clinic in Ohio, discusses the phase I portion of a phase I/II trial testing the smoothened (SMO) inhibitor glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.

Gerds gave a presentation on this study (abstract 258) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta. 

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content
FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Tim Cortese
May 6th 2025
Article

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

American Society for Transplantation and Cellular Therapy
April 24th 2025
Article

Researchers conducted a comprehensive review on how intrinsic T cell characteristics influence CAR-T cell therapy outcomes in hematological malignancies.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

Roman Fabbricatore
March 17th 2025
Article

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies

Roman Fabbricatore
March 17th 2025
Article

Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.